Expansion cohorts in TP53-mutated AML are ongoing (NCT03248479) and a phase 3 trial evaluating magrolimab + AZA in untreated TP53-mutant AML patients is planned [90]. The gene discussed is TP53; the disease is acute myeloid leukemia.